Scott Coleman
Corporate Officer/Principal presso XILIO THERAPEUTICS, INC.
Posizioni attive di Scott Coleman
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2022 | - |
Storia della carriera di Scott Coleman
Precedenti posizioni note di Scott Coleman
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - | - |
Formazione di Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Borsa valori
- Insiders
- Scott Coleman
- Esperienza
